Phostin Therapeutics develops First-In-Class Glycocalyx Modifiers that target glycosylation mechanisms to enhance immune response against aggressive solid tumors. Their Glycosylation inhibitors aim to reduce tumor invasiveness and improve treatment outcomes for cancers and other serious diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Aggressive solid tumors often evade the immune system through mechanisms involving glycosylation, a process that modifies proteins and lipids with sugar molecules. This evasion hinders effective immune responses, contributing to tumor invasiveness and limiting the success of conventional cancer treatments.
Solution
Phostin Therapeutics is developing first-in-class glycocalyx modifiers that target glycosylation mechanisms to enhance the immune response against aggressive solid tumors. By modulating glycosylation, their approach aims to reduce tumor invasiveness, improve immune cell infiltration, and ultimately enhance treatment outcomes. These glycocalyx modifiers are designed to disrupt the tumor's protective glycocalyx layer, making it more vulnerable to immune attack. The company's focus is on developing targeted therapies that can overcome the immune evasion strategies employed by cancer cells.
Target Audience
The primary target audience includes patients with aggressive solid tumors, oncologists, and researchers focused on immuno-oncology and glycosylation-related cancer mechanisms.
Features
- Glycosylation inhibitors designed to reduce tumor invasiveness
- First-in-class glycocalyx modifiers targeting glycosylation mechanisms
- Modulation of the tumor microenvironment to enhance immune cell infiltration
- Development of targeted therapies to overcome immune evasion strategies